ICER chastises J&J for overpricing depression drug esketamine ‘where there is such need for treatment’
Cognizant of the myriad of approved antidepressants that often don’t work, regulators endorsed J&J’s $JNJ pharmaceutical version of the hallucinogenic anesthetic ketamine — esketamine …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
